The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer

Table 2 Current clinical trials (at clinicaltrials.gov) evaluating the combination of RT with immune checkpoint inhibitors

Clinical setting	Clinical trial	Drug	Combination
Resectable locally advanced SCCHN	NCT02641093 phase II	Pembrolizumab	Adjuvant RT/RCT
Resectable locally advanced SCCHN	NCT02296684 phase II	Pembrolizumab	Adjuvant RT/RCT
Locally advanced SCCHN	NCT01935921 phase I	Ipilimumab	Definitive RT + cetuximab
Intermediate/High risk locally advanced SCCHN	NCT01860430 phase Ib	Ipilimumab	Definitive RT + cetuximab
Locally advanced SCCHN	NCT02586207 phase I	Pembrolizumab	Definitive RT + CDDP
locally advanced laryngeal carcinoma	NCT02759575 phase I/II	Pembrolizumab	Definitive RT + CDDP
Intermediate/High risk locally advanced SCCHN	NCT02764593 phase I	Nivolumab	Definitive RT, RT+ CDDP, RT + cetuximab
Intermediate/High risk locally advanced SCCHN	Phase III	Nivolumab	Definitive RT + CDDP
locoregional inoperable recurrence or second primary SCCHN	NCT02289209 phase II	Pembrolizumab	Reirradiation
Advanced metastatic disease (multicohort)	NCT02303990 phase I	Pembrolizumab	RT
Brain metastasis (multicohort)	NCT02669914 phase II	Durvalumab	Stereotactic radiosurgery

ISSN: 2059-7347